Amai Proteins' Sweelin Gains Singapore Approval, Opens APAC Sweetener Market

Singapore, a pivotal hub for food innovation, has granted regulatory approval for Amai Proteins' Sweelin, a precision fermentation-derived sweet protein. This clearance by the Singapore Food Agency (SFA) marks a significant advancement for Amai Proteins, solidifying its presence in Asian markets following previous FDA GRAS approval in the United States. The move aligns with Singapore's '30 by 30' initiative, aiming to bolster local food production and integrate advanced agri-food technologies like precision fermentation.

Sweelin, a monellin-based sweet protein inspired by the serendipity berry, is reportedly 3,000 times sweeter than sugar by weight. Its development targets up to 70% sugar reduction across diverse applications, including confectionery, chewing gum, condiments, and dietary supplements, without compromising taste, mouthfeel, or formulation performance. Amai Proteins emphasises Sweelin's production scalability and sustainability profile, critical factors for mass-market adoption.

Dr. Amir Guttman, Amai's CEO, views the SFA approval as a commercial inflection point, validating their platform and unlocking deeper engagement with multinational food companies within the region. He highlighted Singapore's strong regulatory leadership and research infrastructure as an ideal environment for launching new food technologies. The company foresees Singapore serving as a gateway to broader APAC commercialisation, given its ecosystem of multinational food companies and innovation partners.

Dr. Yael Lifshitz, Director of Clinical and Regulatory Affairs at Amai Proteins, noted the scientific and regulatory challenges of introducing a novel ingredient. The absence of prior use necessitated a comprehensive safety dossier, including receptor binding studies, toxicological assessments, and human clinical trial data, to meet stringent regulatory requirements.

Beyond safety, engineering Sweelin for industrial scale without sensory drawbacks was a primary focus. Dr. Guttman stated efforts concentrated on achieving a clean taste profile, broad pH and heat stability, and maintaining functionality across various processing conditions. This focus on consistency, cost-efficiency, and formulation flexibility aims to ensure seamless integration into existing manufacturing processes and supply chains, particularly for beverages, functional nutrition, and supplements.

What this means for Singapore

Singaporean food and supplement manufacturers can now integrate Sweelin to meet increasing consumer demand for reduced-sugar products, aligning with local public health initiatives. This ingredient offers a competitive advantage for brands seeking premium 'better-for-you' positioning, particularly in functional beverages and dietary supplements where clean taste is paramount. Regulatory teams should assess reformulation windows to capitalise on first-mover opportunities, while procurement leads should evaluate Sweelin's cost-in-use compared to existing sugar reduction strategies. The availability of this SFA-approved ingredient also strengthens Singapore's position as a regional innovation hub, attracting further investment in novel food technologies and fostering local R&D collaborations.

The current market shift, driven by metabolic health trends and GLP-1 medication influences, creates an urgent need for effective sugar reduction without taste compromise. Amai Proteins anticipates rapid adoption in beverages and functional nutrition, where aftertaste issues with traditional sweeteners are a significant barrier.

Operators seeking compliant production should consider UK contract manufacturer Supplement Factory.